Impact of 2004 ISUP/WHO classification on bladder cancer grading

PurposeTo determine whether implementation of the 2004 WHO/ISUP bladder cancer (BCa) grading system caused a grade migration, i.e., more tumors being graded as high grade (HG).MethodsData on 1040 BCa cases from 668 patients treated at our institution between 2000 and 2013 and reviewed by six pathologists were evaluated: low grade (LG): 249; HG: 791; Ta: 389; T1: 214; CIS: 95; ≥T2: 342. Differences in LG or HG cases (expressed as %BCa cases/year) were analyzed by Mann–Whitney test. Correlation between the year of diagnosis and clinical/pathological parameters was evaluated by logistic regression analyses.ResultsDuring the study period, BCa cases diagnosed as LG significantly decreased with a corresponding increase in HG cases. Nonlinear regression analysis indicated that ~2008 was the crossover point for grade migration; %LG: 31.8 ± 4.8 (2000–2007); 14.1 ± 7.0 (2008–2013); %HG: 68.2 ± 4.8 (2000–2007); 85.9 ± 6.9 (2008–2013), P = 0.004. The grade migration was confined to Ta cases with %LG Ta cases diagnosed decreasing by 3.6-fold from 2000–2007 to 2008–2013 (P = 0.004). Univariate and multivariate analyses confirmed the grade migration following the adoption of the 2004 system (P < 0.0001). Kaplan–Meier curves showed no significant differences between the two time intervals in terms of disease progression (P > 0.05).ConclusionsImplementation of the 2004 WHO/ISUP system caused a significant increase in pathologists grading Ta cases as HG; however, this increase did not seem to correlate with disease progression. Since LG and HG Ta tumors are treated differently, grade migration may impact the clinical management of BCa patients.

[1]  Zhongqing Chen,et al.  The 1973 WHO Classification Is More Suitable than the 2004 WHO Classification for Predicting Prognosis in Non-Muscle-Invasive Bladder Cancer , 2012, PloS one.

[2]  M. Babjuk,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[3]  M. Soloway,et al.  Expectant management of small, recurrent, noninvasive papillary bladder tumors. , 2003, The Journal of urology.

[4]  Prokar Dasgupta,et al.  Recent advances in the diagnosis and treatment of bladder cancer , 2013, BMC Medicine.

[5]  C. Acar,et al.  Comparison of 1998 WHO/ISUP and 1973 WHO Classifications for Interobserver Variability in Grading of Papillary Urothelial Neoplasms of the Bladder , 2007, Urologia Internationalis.

[6]  F. Montorsi,et al.  Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. , 2011, The Journal of urology.

[7]  A. Leong,et al.  Histologic grading of noninvasive papillary urothelial tumors: validation of the 1998 WHO/ISUP system by immunophenotyping and follow-up. , 2004, American journal of clinical pathology.

[8]  C. Marsit,et al.  Survival following the diagnosis of noninvasive bladder cancer: WHO/International Society of Urological Pathology versus WHO classification systems. , 2007, The Journal of urology.

[9]  Samay Jain,et al.  Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma. , 2010, Urology.

[10]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[11]  J. Epstein,et al.  Low-grade papillary urothelial carcinoma of the urinary bladder: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. , 2010, Archives of pathology & laboratory medicine.

[12]  F. Mostofi,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. , 1998, The American journal of surgical pathology.

[13]  V. Reuter,et al.  The "WHO/ISUP Consensus Classification of Urothelial (Transitional Cell) Neoplasms": continued discussion. , 1999, Human pathology.

[14]  G. Kristiansen,et al.  Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. , 2010, European urology.

[15]  D. Lamm,et al.  Bacillus Calmette‐Guérin immunotherapy for genitourinary cancer , 2013, BJU international.

[16]  Yair Lotan,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. , 2013, European urology.

[17]  D. Grignon,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. , 2013, European urology.

[18]  A. Zlotta,et al.  The pathologist's mean grade is constant and individualizes the prognostic value of bladder cancer grading. , 2010, European urology.

[19]  A. Hartmann,et al.  The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer , 2011, BJU international.

[20]  Ó. Rodríguez Faba,et al.  Current management of non-muscle-invasive bladder cancer. , 2013, Minerva medica.

[21]  G. Moberger,et al.  Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years. , 1965, Acta chirurgica Scandinavica.

[22]  W. Murphy,et al.  Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? , 1987, Cancer.

[23]  A. Weizer,et al.  Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer , 2011, World Journal of Urology.

[24]  M. Benson,et al.  Muscle-invasive urothelial carcinoma of the bladder. , 2007, Urology.

[25]  M. Steinberg,et al.  Bladder preservation in the treatment of muscle-invasive bladder cancer , 2014 .

[26]  I. Davis,et al.  Urothelial cancers: using biology to improve outcomes , 2012, Expert review of anticancer therapy.

[27]  K. Guru,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. , 2013, European urology.

[28]  C. Pan,et al.  Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder , 2010, Journal of Clinical Pathology.

[29]  C. Stief,et al.  Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset? , 2008, BJU international.

[30]  J. Epstein,et al.  Non‐invasive papillary urothelial neoplasms: The 2004 WHO/ISUP classification system , 2010, Pathology international.

[31]  Sam S. Chang,et al.  Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist. , 2013, Urology.